Loading...
•
Mar 31, 2022
Incyte Q1 2022 Earnings Report
Incyte's Q1 2022 financial results were reported, highlighting a 20% year-over-year increase in total product and royalty revenues, driven by Jakafi, Pemazyre, and Opzelura.
Key Takeaways
Incyte reported a strong first quarter with a 20% increase in total product and royalty revenues, reaching $728 million. Jakafi's net product revenues grew by 17% to $544 million, and Opzelura saw a robust uptake with over 38,000 new patients treated. The company is progressing with its clinical development programs, including regulatory submissions for ruxolitinib cream and advancements in its MPN and GVHD portfolios.
Total product and royalty revenues increased by 20% year-over-year to $728 million.
Jakafi net product revenues grew by 17% year-over-year to $544 million.
Opzelura saw a robust uptake with over 38,000 new patients treated in the first quarter.
The company is on track for submission of the new drug application (NDA) for once-daily ruxolitinib.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Incyte has reaffirmed its full year 2022 financial guidance, which does not include revenue from Opzelura or the impact of any potential future strategic transactions.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...